Moderna (MRNA) Competitors

Takeda Pharmaceutical (NYSE:TAK) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends.

Do analysts rate TAK or MRNA?

Moderna has a consensus price target of $59.00, indicating a potential upside of 80.65%. Given Moderna's stronger consensus rating and higher probable upside, analysts plainly believe Moderna is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Moderna	4 Sell rating(s)	16 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.04

Which has preferable valuation and earnings, TAK or MRNA?

Takeda Pharmaceutical has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$4.58T	0.01	$994.06M	$0.40	37.99
Moderna	$3.20B	3.94	-$3.56B	-$9.28	-3.52

Does the media prefer TAK or MRNA?

In the previous week, Moderna had 15 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 20 mentions for Moderna and 5 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.95 beat Moderna's score of 0.58 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, TAK or MRNA?

Takeda Pharmaceutical has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500.

Does the MarketBeat Community believe in TAK or MRNA?

Moderna received 115 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. However, 56.82% of users gave Takeda Pharmaceutical an outperform vote while only 53.88% of users gave Moderna an outperform vote.

Company	Underperform	Outperform
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%
Moderna	Outperform Votes 215 53.88%	Underperform Votes 184 46.12%

Is TAK or MRNA more profitable?

Takeda Pharmaceutical has a net margin of 4.53% compared to Moderna's net margin of -110.04%. Takeda Pharmaceutical's return on equity of 9.39% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.53%	9.39%	4.53%
Moderna	-110.04%	-28.74%	-21.83%

Do institutionals & insiders believe in TAK or MRNA?

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 11.0% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Moderna beats Takeda Pharmaceutical on 10 of the 19 factors compared between the two stocks.